FOXO pivots to healthcare, revenue spikes but cash crunch, heavy debt and NYSE delisting risk

Snapshot - FOXO Technologies Inc. (NASDAQ: DWIN)

What's happening inside

* Management has pivoted from Labs toward operating healthcare (acquired Myrtle Recovery Centers on June 14, 2024 and Rennova Community Health, Inc. (RCHI) including Scott County Community Hospital - closed Sept 10, 2024).
* Revenue ramp is driven almost entirely by the Healthcare segment (hospital + behavioral health); Labs revenue remains immaterial.
* Company executed multiple financings, note conversions and preferred issuances to cover operations; many financings carry heavy discounts, default penalties and conversion/anti‑dilution features.
* Material going‑concern risk: working capital deficit, low cash, several defaulted/negotiated related‑party notes and ongoing legal items. Management is actively raising capital and using equity in lieu of cash in many settlements/fees.
* Recent corporate actions: reverse stock splits (1‑for‑10 and 1‑for‑1.99), significant preferred stock issuances/conversions, and NYSE delisting proceedings with trading moved to OTC (subsequent event).

Key numbers & facts (as reported, June 30, 2025)

* Total assets: $50,019,356 (up from $41,708,071 at 12/31/24).
* Cash & cash equivalents: $321,789 (68,268 at 12/31/24).
* Accounts receivable, net: $4,921,076 (gross $17,005,579; contractual allowances $11,079,103; doubtful $1,005,400). Includes $2.5M THIP receivable.
* Goodwill: $31,301,432 (25,463,948 at 12/31/24).
* Total liabilities: $36,341,517 (36,436,260 at 12/31/24). Current liabilities: $32,899,157.
* Related‑party notes payable: $8,544,185 (major exposure to RHI and affiliates).
* Working capital deficit: ~$27.3 million.
* Total stockholders' equity: $13,677,839 (5,271,811 at 12/31/24).

Income statement highlights - quarter and six months

* Net revenues (Q2 2025): $5,218,373 vs $27,474 (Q2 2024). Six months: $8,388,293 vs $34,654 - huge revenue increase due to acquisitions (RCHI + Myrtle).
* Direct costs (Q2): $1,975,325; SG&A (Q2): $2,616,866; total operating expenses (Q2): $4,651,252.
* Income from operations (Q2): $567,121 (improvement from operating loss of $1,589,569 prior year). Six months: operating loss narrowed to $(979,859) from $(2,768,237).
* Interest expense (Q2): $1,008,751 (six months: $1,898,543) - large financing cost burden.
* Non‑operating items (six months): $1,863,834 gain from extinguishment of Senior PIK Notes (non‑cash benefit from exchanging debt to Series B preferred).
* Net loss attributable to FOXO (Q2): $(522,021); six months: $(1,138,479). Net loss per share (Q2): $(0.21) (basic & diluted).

Positive aspects of the income statement / operations

* Revenue growth: rapid top‑line increase driven by Healthcare acquisitions - Q2 revenue >$5.2M, six‑month revenue >$8.3M versus near zero prior year periods.
* Operating improvement: swing to positive operating income for the quarter ($567k) thanks largely to healthcare revenue and THIP receipt ($2.5M included).
* Non‑cash gain from restructuring debt (Senior PIK Notes) improved six‑month results by $1.86M - reduces cash debt burden.

Negative aspects of the income statement / risks

* Still unprofitable at the net level: six‑month net loss $1.14M and net loss to common (after deemed dividends and undeclared preferred dividends) larger - common shareholders facing meaningful losses.
* Heavy interest expense: $1.9M for six months - financing costs are a significant drag on earnings and cash flow.
* Significant non‑operating adjustments and deemed dividends (anti‑dilution triggers) reduce EPS and common shareholder value - material dilutive potential remains (antidilutive equivalents ~79M shares reported).
* Revenue concentration: healthcare lift tied to government payment (THIP) and acquisitions - collection risk (large gross AR and big contractual allowances) and reimbursement uncertainty.
* Cash conversion problem: accounts receivable increased materially and operating cash flow used $3.7M in six months despite reported revenue.

Immediate balance‑sheet & liquidity issues to watch

* Low cash balance ($321,789) vs operating cash burn and near‑term debt payments; net cash from financing was required in period.
* Working capital deficit of ~$27.3M; significant current liabilities including accrued payroll & past‑due payroll taxes (accrued payroll includes ~ $5.5M past due payroll taxes and penalties).
* Large related‑party indebtedness ($8.54M) and several notes in default or under negotiation (including RCHI notes).
* Potential equity dilution: ongoing conversions of preferred and notes into common (series A/B/C/D activity) and large pool of antidilutive/common equivalents; preferred undeclared dividends recorded.

What to watch next (catalysts and risks)

* Cash raises or debt restructuring - company repeatedly relies on equity/note conversions; success/failure will determine going‑concern outcome.
* AR collections and final settlements of THIP and Medicare cost reports - improve operating cash flow if collected timely.
* Progress on extending or curing defaulted related‑party notes (RHI) and reduction of payroll tax liabilities.
* Regulatory / market access: NYSE delisting proceedings and OTC transfer (subsequent event) - liquidity and investor interest will be affected.
* Integration performance of RCHI/SCCH and Myrtle - sustained operating margins and cash generation from hospitals are required to stabilize finances.

Bottom line: The company has materially increased revenue through targeted healthcare acquisitions and showed a quarter of positive operating income, but remains loss‑making at the net level, highly leveraged, and cash‑constrained with a working capital deficit and significant near‑term obligations. The path to stability depends on collections, further financing or debt/equity restructuring, and successful integration of the healthcare businesses.